We Embody a Legacy of Incredible Discoveries, Exploring the Boundaries of Innovation and Science
At Zenovel, we integrate our extensive expertise across a wide range of domains, from Good Clinical Practice to Regulatory Affairs, to present valuable insights and thought leadership. Each blog reflects our intense dedication to innovation, offering a forum to share our perspectives, groundbreaking ideas, and industry expertise. Through our blogs, we hope to uplift, inform, and support scientific, medical, and pharmaceutical innovation.
The year 2026 represents a pivotal moment for artificial intelligence in clinical research, with generative AI transitioning from a novel
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of
Pharmaceutical startups encounter a challenging journey from laboratory breakthroughs to marketable products, facing significant scientific and regulatory hurdles. A sound
Health Canada’s Good Manufacturing Practices Guide for Drug Products (GUI-0001) is essential for pharmaceutical companies operating in or exporting to
In generic drug development, the biggest delays rarely come from what sponsors do not know. They come from what they
In pharmaceutical development, the acronyms GMP, GCP, and GLP represent the “Golden Trio” of quality standards, ensuring that every drug
In the ever- changing pharmaceutical sector, studies of bioavailability (BA) and bioequivalence (BE) are essential to the approval of both name-brand and generic medications. BA/BE studies have grown in significance during the last thirty years, becoming essential for guaranteeing the safety and therapeutic effectiveness of pharmaceutical goods. Since these studies
Good Manufacturing Practices Audit: At Zenovel, we prioritizes maintaining high quality standards in the pharmaceutical supply chain through GMP audits, ensuring compliance with health authority regulations, industry best practices, and current standards. As regulatory requirements evolve, there’s a growing need for enhanced vigilance and Quality Risk Management during the audit
Overview of Regulatory Oversight in Life Sciences and Pharmaceutical Companies Regulatory agencies including the FDA, EMA, PMDA, HPRA, CDSCO, and others keep a vigilant eye on the life sciences and pharmaceutical sector. These organisations are committed to safeguarding patient safety and drug-product quality. In fiscal year 2023, the FDA
Understanding Nitrosamine Impurities in Pharmaceuticals: Nitrosamines, particularly N-nitrosamines, are probable or possible human carcinogens. They can form during the synthesis of active pharmaceutical ingredients (APIs) or during the storage of finished drug products. FDA guidance emphasizes the need for risk assessment, mitigation strategies, and regulatory compliance to control nitrosamine levels.
Introduction: In-process monitoring is a critical component of ensuring the quality and reliability of BA/BE studies, especially those involving drug-drug interactions (DDIs). For DDI studies, in-process monitoring is particularly crucial due to the complex nature of interactions, the need for precise data, and the potential impact on patient safety. Key
Abstract For the past few years, regulatory bodies, industry advocacy groups, and private companies have been tackling the concept of incorporating risk into the design of clinical trials and customizing monitoring strategies based on those risks to achieve higher-quality outcomes. Regulatory guidance like ICH and FDA encourag sponsors to adopt
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Write to us : bd@zenovel.com
Copyright © 2026 Zenovel. All rights reserved.
